Showing results (111-120 of 157) with videos related to
Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2015
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyTony Mok, Yi-Long Wu, Jin Soo Lee, et al.The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON StudyMelissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung CancerSuresh Senan, Anthony Brade, Lu-Hua Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V Liu, Martin Reck, Aaron S Mansfield, et al.Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.Pageof 16